Novo Nordisk Gains 3.4 Billion in the First Quarter, 28% more Compared to Q1 2023

Novo Nordisk maintains rapid growth. The Danish pharmaceutical company reports profits of 3.4 billion euros in the first quarter of 2024, 28% more than the same period of the previous year. Operating profits, on the other hand, increased by 27%, to 4.27 billion euros.

Net sales stood at 8.76 billion euros, which implies an increase of 22% compared to the first quarter of 2023, thanks to the sales of Novo Nordisk’s drugs against diabetes, Ozempic and Wegovy, which have become popular to address weight losses.

With this data in hand, Novo Nordisk raises its forecasts for 2024, estimating that its operating profit will grow between 22% and 30% and its sales between 19% and 27% .

Novo Nordisk wants to market Wegovy, one of its antidiabetics, as a drug to treat cardiovascular ailments

Novo Nordisk’s diabetes drugs have made the pharmaceutical company the largest European company in terms of capitalization. The demand is such that the Danish company has bought the contract medicine producing company Catalent, until now its Wegovy supplier. It did so through its parent company, Novo Holdings, and for the amount of 10.66 billion euros . And the potential of this drug does not end there.

Novo Nordisk wants Wegovy to gain a foothold in the offer of treatments for cardiovascular pathologies. This was announced by his CEO, Lars Fruergaard Jorgensen, in a meeting with investors and analysts at its headquarters in Copenhagen.

The decision is based on a recent peer-reviewed study that indicates that semaglutide, the compound in Wegovy, could reduce the effects of cardiovascular diseases by up to 20%.

__

(Featured image by Ri_Ya via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us